GlobeNewswire

Nuvaira Announces Oral Presentation at ERS International Congress Discussing Significance of Targeted Lung Denervation to Treat COPD

Del

Results from AIRFLOW-2 Trial Reveal Reduction in Exacerbations and other Respiratory Adverse Events

PARIS, Sept. 18, 2018 (GLOBE NEWSWIRE) -- Nuvaira, a developer of medical devices to treat obstructive lung diseases, announced the acceptance of a clinical abstract by the European Respiratory Society (ERS) for oral presentation at the 28th International Congress 2018 in Paris. Co-principal Investigator, Dirk-Jan Slebos, M.D., Ph.D., from the University Medical Center Groningen in the Netherlands, today will make the first public presentation of results from the AIRFLOW-2 clinical trial (NCT#02058459), the first multi-center, double-blind, randomized, sham-controlled study of Targeted Lung Denervation (TLD) using the Nuvaira™ Lung Denervation System to treat patients with moderate to severe COPD.

“Results from this phase II trial demonstrate a significant reduction in respiratory adverse events such as COPD exacerbations and hospitalizations of greater than 50 percent,” said Dr. Slebos. “I believe these results may have important implications for COPD sufferers and their overall quality of life, as well as for healthcare costs, as there is significant expense associated with exacerbations and hospitalizations.

“TLD is a one-time medical procedure, and it’s the first to target the whole lung by bronchoscopically disrupting parasympathetic nerves to promote airway dilation to make it easier for patients to breathe,” continued Dr. Slebos. “This novel lung denervation system may offer patients who suffer from COPD a long-term treatment that has added effect on top of medical management.”  

The oral presentation entitled, “A double-blind, randomized, sham-controlled study of Targeted Lung Denervation in patients with moderate to severe COPD,” by Dr. Slebos et al., takes place today at 15:00 CEST in room 7.3Z2 as part of the session on “Interventional pulmonology highlights in 2018: ELVR, TLD and BT” (Session 496, Abstract no. OA4929) at the Paris Expo Porte de Versailles.

“We are gratified to have had a clinical abstract on results of the AIRFLOW-2 trial accepted for oral presentation at the ERS International Congress, the largest worldwide meeting of leaders in respiratory medicine,” said Martin Mayse, M.D., co-founder and chief technology officer of Nuvaira. “After proving safety and feasibility of TLD in earlier trials, this sham-controlled trial was the logical next step to further study the potential effectiveness of TLD for patients.”

Nuvaira also hosted an industry mini-symposium at the ERS Congress on Monday evening, which focused on TLD as a one-time treatment for COPD and asthma. The program was co-chaired by Alvar Agustí, M.D., Ph.D., director of the Thorax Clinic Institute at Hospital Clinic in Barcelona, and Professor Felix Herth, M.D., Ph.D., chairman of the Division of Pulmonology and Respiratory Care Medicine at the Thoraxklinik in Heidelberg.

Five medical experts presented clinical findings at the mini-symposium on topics that included: neural control of airway smooth muscle, mechanism of action and the Nuvaira Lung Denervation System, TLD in COPD and data from the AIRFLOW-1 and AIRFLOW-2 trials, TLD in severe asthma, and information regarding the upcoming AIRFLOW-3 pivotal trial, which is planned for sites in Europe, Canada and the U.S.

About COPD
COPD is the umbrella term used to describe a group of diseases such as small airway disease (chronic bronchitis) and emphysema, characterized by chronic and incompletely reversible airway obstruction that interferes with normal breathing. It
is estimated that COPD affects more than 300 million people globally1 ,[2].

Pharmacological treatment is the approach for most patients today. Inhaled drugs are used once or twice daily to relax and temporarily open airways. Other forms of treatment include pulmonary rehabilitation, oxygen administration and surgical intervention. The annual financial burden of lung disease in Europe is €141 billion and COPD accounts for almost half3. In the United States, COPD costs are estimated to be more than $50 billion annually4.

About AIRFLOW-2
The AIRFLOW-2 (NCT#02058459) sham-controlled trial was designed to assess the safety of TLD in patients suffering from moderate to severe COPD. The trial included 82 patients at 15 institutions throughout Western Europe. Enrollment has been completed and long-term follow-up is ongoing. The principal investigators are Dirk-Jan Slebos, M.D., Ph.D., University Medical Center, Groningen, The Netherlands and Arschang Valipour, M.D., Ph.D., Otto Wagner Spital, Vienna, Austria.

About Nuvaira
Nuvaira is a privately held company headquartered in Minneapolis, Minn. The company has developed the Nuvaira™ Lung Denervation System to address chronic obstructive pulmonary disease (COPD) and asthma by treating the overactive airway nerves during Targeted Lung Denervation* (TLD). Nuvaira received CE Mark approval for its Nuvaira Lung Denervation System for use during TLD in January 2016. More information may be found at www.Nuvaira.com.

Media Inquiries:
Amy Wolter
+1 (763) 450-5676
info@nuvaira.com

*Targeted Lung Denervation (TLD) is currently under clinical investigation for chronic obstructive pulmonary disease and is not yet commercially available.
Nuvaira is a trademark of Nuvaira, Inc.
_______________________________________

1 Global Chronic Obstructive Pulmonary Disease Epidemiology and Patient Flow - 2017. Fore Pharma.

2 http://www.efanet.org/get-advice/copd

3 http://www.efanet.org/get-advice/copd

4 Global Initiative for Chronic Obstructive Lung Disease (GOLD) 2017 Report

A photo accompanying this announcement is available at http://www.globenewswire.com/NewsRoom/AttachmentNg/7a4d08f3-b50c-4544-bc2c-cf5b7041311a

Om GlobeNewswire

GlobeNewswire
GlobeNewswire
One Liberty Plaza - 165 Broadway
NY 10006 New York

https://globenewswire.com

GlobeNewswire is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.

Følg saker fra GlobeNewswire

Registrer deg med din epostadresse under for å få de nyeste sakene fra GlobeNewswire på epost fortløpende. Du kan melde deg av når som helst.

Siste saker fra GlobeNewswire

New Samsung Galaxy Ultrasonic Fingerprint System World’s First to Achieve FIDO Biometric Certification20.2.2019 21:30:00Pressemelding

Samsung’s new “in-display” Ultrasonic Fingerprint system certified by FIDO Alliance as meeting globally recognized standards for biometric recognition performance and Presentation Attack Detection (PAD) MOUNTAIN VIEW, Calif., Feb. 20, 2019 (GLOBE NEWSWIRE) -- The FIDO Alliance announced today that the Samsung Galaxy S10 and S10+ smartphones are the first products to feature certification from the FIDO Alliance’s new Biometric Component Certification Program. This certification validates that the new in-display fingerprint recognition system meets industry standards for user verification and detecting presentation (or “spoof”) attacks. “As mobile devices increasingly become our primary means of storing sensitive information and conducting critical transactions, the industry leaders in FIDO Alliance have determined the market needs a standard-based means to assess the efficacy of biometric certification components -- which is why we recently launched our Biometric Component Certification

Infovista Expands 5G Network Testing and Planning Capabilities20.2.2019 15:00:00Pressemelding

ASHBURN, Va., Feb. 20, 2019 (GLOBE NEWSWIRE) -- Infovista, the leader in modern network performance, today announced new versions of its TEMS Investigation and Planet solutions. With this announcement, Infovista is the only vendor offering the complete 5G portfolio comprising full network planning and testing in a single, integrated platform. Infovista is now uniquely positioned to help mobile network operators roll out 5G NR networks by including the ability to provide integrated Geodata, 5G Planning and Network Testing capabilities. Tweet This: @Infovista expands 5G network testing and planning capabilities, offering complete 5G portfolio in a single, integrated platform: https://bit.ly/2Nm8Rup With the new release of TEMS Investigation, Infovista introduces support for 5G smartphones based on the Qualcomm X50 chipset. With initial support of Qualcomm based devices and plans for agnostic device support, customers will be able to choose between different test devices and scanners to s

Reminder: Constellation Brands to Present at Consumer Analyst Group of New York Conference, February 20, 201920.2.2019 14:30:00Pressemelding

VICTOR, N.Y., Feb. 20, 2019 (GLOBE NEWSWIRE) -- Constellation Brands, Inc. (NYSE: STZ and STZ.B), a leading beverage alcohol company, reiterates that Bill Newlands, president and chief operating officer, and David Klein, chief financial officer, will present at the Consumer Analyst Group of New York (CAGNY) conference on Wednesday, February 20, 2019, at the Boca Raton Resort & Club in Florida. The presentation is scheduled to begin at 3:00 p.m. EST and is expected to cover the company’s strategic business activities, including a discussion on portfolio strategy; financial and operational performance; and outlook for the future, including a discussion on the accounting methodology and potential impact on fourth quarter fiscal year 2019 non-cash equity in earnings from the company’s Canopy Growth investment. A live audio webcast of the presentation can be accessed on the company’s website at www.cbrands.com by following the instructions in the “Investors” section under “Events & Presenta

Fortuna provides construction update at its Lindero gold project in Argentina20.2.2019 11:00:00Pressemelding

VANCOUVER, British Columbia, Feb. 20, 2019 (GLOBE NEWSWIRE) -- Fortuna Silver Mines Inc. (NYSE: FSM) (TSX: FVI) is pleased to provide an update on construction activities at its 100 percent owned Lindero gold Project located in the Province of Salta, Argentina. Following the cessation of unusually heavy rainfall in Salta Province in recent weeks, which resulted in damage to the road leading to the Lindero Project site (see Fortuna news release dated February 7, 2019), management is pleased to report that the road has been repaired and on February 18th the mobilization of personnel and materials to the project site resumed. Mr. Jorge A. Ganoza, President, CEO and Director, commented, “Abnormal rains and electrical thunder storms not seen in a decade in the region are impacting our construction activities and schedule projections. A large amount of the float in the construction schedule has been consumed due to a slow start and ramp-up in excavations at the leach pad and crushing plant,

DoubleVerify Acquires Digital Video Technology Company, Zentrick20.2.2019 09:00:00Pressemelding

Solving 30% breakage in video ad delivery NEW YORK and GHENT, Belgium, Feb. 20, 2019 (GLOBE NEWSWIRE) -- DoubleVerify, the leading independent provider of marketing measurement software and analytics, today announced that it has acquired Zentrick, a digital video technology company that provides middleware solutions to drive the seamless execution and performance of online video advertising for the world’s largest brands, platforms and publishers. The Zentrick engineering teams will continue to operate from offices in Ghent, Belgium. The transaction was completed as an all cash, all stock offer on February 15, 2019. Video advertising spend soared to $28 Billion in 2018. However, the ecosystem necessary to support the growth in video ad delivery has become highly fragmented. Today over 30% of video ads that are sold are unable to be delivered by publishers due to various forms of technical ‘breakage’ in the ad delivery chain – an issue that’s particularly acute in the key areas of mobil

ADC Therapeutics Announces First Patient Dosed in Phase I Clinical Trial of ADCT-402 (loncastuximab tesirine) and Ibrutinib in Patients with Advanced Diffuse Large B-Cell Lymphoma or Mantle Cell Lymphoma20.2.2019 07:00:00Pressemelding

Combination trial to evaluate safety and anti-tumor activity of agents that target B-cell cancers LAUSANNE, Switzerland, Feb. 20, 2019 (GLOBE NEWSWIRE) -- ADC Therapeutics, an oncology drug discovery and development company that specializes in the development of proprietary antibody drug conjugates (ADCs), today announced that the first patient has been dosed in a Phase I clinical trial evaluating the safety, tolerability, pharmacokinetics and anti-tumor activity of ADCT-402 (loncastuximab tesirine) in combination with Pharmacyclics LLC’s ibrutinib in patients with advanced diffuse large B-cell lymphoma (DLBCL) or mantle cell lymphoma (MCL). ADCT-402, an ADC designed to target and kill CD19-expressing malignant B-cells, is also being evaluated in an ongoing pivotal Phase II clinical trial in patients with relapsed or refractory (R/R) DLBCL and a Phase I clinical trial in combination with IMFINZI® (durvalumab) in patients with multiple types of R/R non-Hodgkin lymphoma. Ibrutinib, a sma